UroGen Pharma Ltd.
URGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001668243
In the last 90 days, UroGen Pharma Ltd. insiders filed 0 open-market purchases and 4 sales; 190 institutions reported holding it in 13F filings for Q2 2026, worth $1.56B in total; ARK Invest is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding UroGen Pharma Ltd. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 115 | 1 | 128 | +14 |
| Shares | 38.2M | 2.19M | 35.1M | −903.2K (−2.5%) |
| Value | $641.4M | $36.8M | $445.7M | −$158.9M (−26.3%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (26)
Institutions that held UroGen Pharma Ltd. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (12)
Institutions that held UroGen Pharma Ltd. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Ra Capital Management, L.P. | 3,083,430 | $51.7M |
| Laurion Capital Management LP | 160,600 | $2.69M |
| Atom Investors LP | 144,780 | $2.43M |
| Alyeska Investment Group, L.P. | 100,000 | $1.68M |
| Walleye Capital LLC | 57,610 | $966.7K |
| Marshall Wace, LLP | 42,841 | $718.9K |
| Oppenheimer & Co Inc | 19,323 | $324.2K |
| ProShare Advisors LLC | 11,888 | $199.5K |
| D. E. Shaw & Co., Inc. | 10,843 | $181.9K |
| Allspring Global Investments Holdings, LLC | 5,298 | $88.9K |
| Lindbrook Capital, LLC | 87 | $1.46K |
| Toronto Dominion Bank | 6 | $101 |
Not filed for Q3 2024 yet (1)
Institutions that held UroGen Pharma Ltd. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 2,193,950 | $36.8M |